Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CTSK | P43235 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337351 | 1.00 | PARP1 (0.54) | PARP1ATMALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL336577 | 1.00 | PARP1 (0.54) | PARP1ATMALDH1A1USP2SMN1; SMN2 | |
| SCHEMBL20161897 | 0.91 | PARP1 (0.49) | PARP1ATMALDH1A1SMN1; SMN2CTSK | |
| SCHEMBL20139067 | 0.91 | PARP1 (0.49) | PARP1ATMALDH1A1SMN1; SMN2CTSK | |
| SCHEMBL20139068 | 0.91 | PARP1 (0.49) | PARP1ATMALDH1A1SMN1; SMN2CTSK | |
| SCHEMBL29527992 | 0.89 | PARP1 (0.50) | PARP1 | |
| SCHEMBL29947739 | 0.89 | PARP1 (0.50) | PARP1 | |
| SCHEMBL4312622 | 0.88 | PARP1 (0.52) | PARP1ATMALDH1A1 | |
| SCHEMBL5081566 | 0.88 | PARP1 (0.52) | PARP1ATMALDH1A1 | |
| SCHEMBL4309075 | 0.88 | PARP1 (0.52) | PARP1ATMALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104046246-B | The chemical-mechanical planarization of tungsten-containing substrate | 气体产品与化学公司 | 2016-06-15 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS AG (CH) | 2025-09-11 | — | — | US | disclosed |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-09-04 | — | — | US | disclosed |
| WO-2025111547-A1 | 2,3-DIHYDROPYROLLOPYRIDINE CARBOXAMIDE COMPOUNDS AND METHODS OF USE THEREOF | RGENTA THERAPEUTICS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2025-03-18 | — | — | US | disclosed |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2025-01-02 | — | — | US | disclosed |
| US-20240425498-A1 | PARG INHIBITORY COMPOUNDS | FORX THERAPEUTICS AG (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| CN-101679275-A | New compounds 707 and their uses | ASTRAZENECA AB | 2010-03-24 | — | — | CN | disclosed |
| WO-2009079490-A1 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF HETEROCYCLIC SUBSTITUTED PIPERAZINES WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION (US) | 2009-06-25 | — | — | WO | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-7432268-B2 | 17β-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | SCHERING CORPORATION (US) | 2008-10-07 | — | — | US | disclosed |
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION AND PHARMACOPEIA, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | SCHERING CORPORATION | 2008-02-14 | — | — | US | disclosed |
| US-6638936-B1 | Treatment of obesity in mammals, comprising administering to mammal in need of such treatment, treatment of obsessive compulsive disorder in mammals, comprising administering to a mammal treatment of depression in mammals | ELI LILLY AND COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1204658-B1 | BENZOFURYLPIPERAZINE SEROTONIN AGONISTS | LILLY CO ELI (US) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058343-A1 | HETEROCYCLIC SUBSTITUTED PIPERAZINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | PARP1 2975/4885ATM 4068/4885ALDH1A1 1721/4885 |
| US-20240425498-A1 | PARG INHIBITORY COMPOUNDS | PARG, PLG, PPIG | PARP1 51/4885ATM 3005/4885ALDH1A1 2097/4885 |
| US-12252482-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | PARP1 3115/4885ATM 4359/4885ALDH1A1 1243/4885 |
| US-20250282762-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | PARP1 3115/4885ATM 4359/4885ALDH1A1 1243/4885 |
| US-20250276964-A1 | Benzisoxazole Derivatives and Uses thereof | HBZ, ZFX, WIZ | PARP1 3469/4885ATM 4701/4885ALDH1A1 853/4885 |
| US-20250066389-A1 | HETEROCYCLIC AMIDES AND METHODS OF USING THE SAME | SNRPA, SF3B5, RBM17 | PARP1 1592/4885ATM 2500/4885ALDH1A1 1405/4885 |
| US-20080039474-A1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRIDINE COMPOUNDS WITH CXCR3 ANTAGONIST ACTIVITY | CXCR3, CXCR1, ACKR3 | PARP1 3084/4885ATM 3753/4885ALDH1A1 2229/4885 |
| US-20100130492-A1 | MORPHOLINOPURINE DERIVATIVES | MTOR, RICTOR, PIK3R1 | PARP1 1123/4885ATM 1142/4885ALDH1A1 2409/4885 |
| US-20250002479-A1 | PYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF | HBZ, ZFX, WIZ | PARP1 3115/4885ATM 4359/4885ALDH1A1 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.